![]() The studies-which tested the PARP inhibitors niraparib (Zejula), olaparib (Lynparza), and veliparib, respectively-involved women with high-grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer. Now, results from three new clinical trials show that the drugs might also benefit women who are newly diagnosed with advanced ovarian cancer. The approval was based on findings from the PAOLA-1 trial, results of which are described in this Cancer Currents story.Ärugs known as PARP inhibitors are used to treat some women with advanced ovarian cancer that has returned after earlier treatment. These alterations must be determined using a specific FDA-approved test, the agency explained in a statement. ![]() In addition, the olaparib–bevacizumab treatment can be used only to treat women who have certain genetic alterations. The approval covers the use of olaparib in combination with bevacizumab (Avastin) in women whose tumors shrink partially or completely after initial treatment with chemotherapy containing a platinum drug. UPDATE: On May 8, 2020, the Food and Drug Administration (FDA) expanded the approval of olaparib (Lynparza) for the initial treatment of women with advanced ovarian cancer.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |